콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

SML3523

Sigma-Aldrich

Solriamfetol hydrochloride

≥98% (HPLC)

동의어(들):

(2R)-2-Amino-3-phenylpropyl carbamate hydrochloride, (R)-2-amino-3-phenylpropylcarbamate hydrochloride, ADX-N 05, ADX-N05, JZP 110, JZP-110

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C10H14N2O2 ·HCl
CAS Number:
Molecular Weight:
230.69
MDL number:
UNSPSC 코드:
12352200
NACRES:
NA.04

Quality Level

분석

≥98% (HPLC)

형태

powder

약물 제어

USDEA Schedule IV

저장 조건

desiccated

색상

white to beige

solubility

DMSO: 2 mg/mL, clear

저장 온도

2-8°C

생화학적/생리학적 작용

Solriamfetol (JZP-110) is a potent and selective dual reuptake inhibitor at dopamine and norepinephrine transporters that increases extracellular levels of dopamine and norepinephrine in vivo. Solriamfetol is a wake-promoting agent.

주의사항

Hygroscopic

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Richard K Bogan et al.
Sleep medicine, 16(9), 1102-1108 (2015-08-25)
JZP-110 is a wake-promoting agent with dopaminergic and noradrenergic activity. This double-blind, crossover study, randomized adults with narcolepsy with or without cataplexy (N = 33) to placebo or JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4).
Michelle G Baladi et al.
The Journal of pharmacology and experimental therapeutics, 366(2), 367-376 (2018-06-13)
Excessive sleepiness (ES) is associated with several sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these conditions is highlighted by the clinical use of US Food and Drug Administration-approved drugs that act
Stefano de Biase et al.
Expert opinion on investigational drugs, 26(8), 953-963 (2017-07-21)
Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. While non-pharmacological treatments are sometimes helpful, more than 90% of narcoleptic patients require a pharmacological treatment.

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.